HER2 signaling is a driver of tumor cell proliferation and survival.1,2

The HER2/HER3 heterodimer delivers the most potent signal for proliferation in tumor cells that overexpress HER2.2-4

HER2 targeting is an opportunity2,3

HER2 overexpression and/or amplification is an oncogenic driver in multiple tumor types, as well as a potential therapeutic target.

HER2 positivity across select cancers5-8

HER2 overexpression and/or amplification graph showing HER2 positivity across select cancers

Discover the importance of testing for HER2 in mCRC.

Join our list of labs that test for HER2 in mCRC.

Optimizing treatment through simultaneous HER2 inhibition

HER = human epidermal growth factor receptor; mCRC = metastatic colorectal cancer.

References: 1. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007;97(4):453-457. doi:10.1038/sj.bjc.6603910 2. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146(3):264-275. doi:10.1016/j.jconrel.2010.04.009 3. Siena S, Sartore-Bianchi A, Marsoni S, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29(5):1108-1119. doi:10.1093/annonc/mdy100 4. Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996;15(10):2452-2467. 5. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X 6. Martínez-Sáez O, Prat A. Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract. 2021;17(10):594-604. doi:10.1200/OP.21.00172 7. Kang A, Bloudek L, Mordi U, et al. Systematic literature review of HER2 amplification/overexpression in colorectal cancer. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 18-21, 2021; Denver, CO. 8. Zhao J, Xia Y. Targeting HER2 alterations in non–small-cell lung cancer: a comprehensive review. JCO Precis Oncol. 2020;4:411-425. doi:10.1200/PO.19.00333